AIM ImmunoTech Inc. Cash Flow Statement
AIM|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
AIM ImmunoTech Inc. used $11M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$14.0M | -$29.0M | -$19.4M | -$19.1M | -$14.4M | -$14.4M | -$9.4M | -$9.8M | -$15.2M | -$7.5M | -$15.2M | -$17.4M | -$16.2M | -$17.4M | -$7.2M |
| Depreciation & Amortization | - | $39.0K | $38.0K | $659.0K | $665.0K | - | - | - | $941.0K | - | - | - | - | - | $359.0K |
| Operating Cash Flow | -$11.0M | -$21.3M | -$16.1M | -$14.0M | -$10.4M | -$10.4M | -$9.1M | -$10.6M | -$16.1M | -$7.4M | -$16.1M | -$14.0M | -$16.8M | -$13.1M | -$9.3M |
| Capital Expenditures | - | $18.0K | $86.0K | $41.0K | $22.0K | $22.0K | $68.0K | $51.0K | $240.0K | $160.0K | $240.0K | $504.0K | $898.0K | $5.8M | $332.0K |
| Free Cash Flow | - | -$21.3M | -$16.2M | -$14.0M | -$10.4M | -$10.4M | -$9.1M | -$10.7M | -$16.3M | -$7.5M | -$16.3M | -$14.5M | -$17.7M | -$18.9M | -$9.6M |
| FCF Margin | - | -10537.1% | -11485.1% | -10374.8% | -6374.2% | -6374.2% | -6525.0% | -2913.1% | -12250.4% | -8195.7% | -12250.4% | -7344.2% | -11818.7% | -8869.0% | -8674.8% |